Rat Cytosolic Epoxide Hydrolase

  • Franz Oesch
  • Ludwig Schladt
  • Renate Hartmann
  • Christopher Timms
  • Walter Wörner
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 197)


Rat liver microsomal and cytosolic epoxide hydrolase may be distinguished through differences in substrate specificity: styrene 7,8-oxide is preferentially hydrolyzed by the microsomal form, while trans-stilbene oxide is the prefered substrate for cytosolic epoxide hydrolase. Large interindividual differences in the specific activity of SpragueDawley (outbred strain) liver cytosolic epoxide hydrolase were observed, varying from 2 to 77 pmol/min x mg protein. Interindividual variations were much lower for microsomal epoxide hydrolase. The specific activity of Fischer F-344 (inbred strain) liver cytosolic epoxide hydrolase varied only by a factor of 2. The specific activity of cytosolic epoxide hydrolase using trans-stilbene oxide as the substrate was highest in kidney and heart, followed by liver, brain, lung, testis, and spleen. For microsomal epoxide hydrolase, the specific activity was much lower in extrahepatic tissues than in liver. None of the commonly used inducers of xenobiotic metabolizing enzymes caused significant changes in rat liver cytosolic epoxide hydrolase. However, peroxisome proliferating drugs were found to drastically increase cytosolic epoxide hydrolase activity. Treatment for one week with a diet containing clofibrate (0.25%), tiadenol (0.5%) or acetylsalicylic acid (1%) caused a 8, 13 and 5 fold increase in cytosolic epoxide hydrolase activity respectively in the liver which parallelled the induction of peroxisomal ß-oxidation activity (13, 19 and 5 fold, respectively).


Interindividual Variation Epoxide Hydrolase Styrene Oxide Cyclohexene Oxide Cholesterol Oxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Synyder, D. V. Parke, J. J. Kosicis, D. J. Jollow, C. G. Gibson and C. G. Witmer, Advances in Experimental Medicine and Biology. Biological Reactive Intermediates-II, Chemical Mechanism and Biological Effects. Plenum Press, New York (1982).Google Scholar
  2. 2.
    F. Oesch, Mammalian epoxide hydrases. Inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compound, Xenobiotica 3: 305 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    W. B. Jakoby and W. H. Habig, Glutathione transferases, in: “Enzymatic Basis of Detoxication”, Vol. 2, W. B. Jakoby, ed., pp. 63–94. Academic Press, New York (1980).Google Scholar
  4. 4.
    C. Timms, F. Oesch, L. Schladt and W. Wörner, Multiple forms of epoxide hydrolase, in: “Proceedings of the 9th International Congress of Pharmacology”, J.F. Mitchell, W. Paton, P. Turner, eds., Macmillan Press, Londen (1984).Google Scholar
  5. 5.
    A. Y. H. Lu and G. T. Miwa, Molecular properties and biological functions of microsomal epoxide hydrase, Ann. Rev. Pharmacol. Toxicol. 20: 513 (1980).CrossRefGoogle Scholar
  6. 6.
    F. Oesch, C. W. Timms, C. H. Walker, T. M. Guenthner, A. J. Sparrow, T. Watabe and C. R. Wolf, Existence of multiple forms of microsomal epoxide hydrolases with radically different substrate specifities, Carcinogenesis 5: 7 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    W. Levin, D. P. Michaud, P. E. Thomas and D. M. Jerina, Distinct rat hepatic microsomal epoxide hydrolases catalyze the hydration of cholesterol 5,6a-oxide and certain xenobiotic alkene and arene oxides, Archs. Biochem. Biophys. 220: 485 (1983).CrossRefGoogle Scholar
  8. 8.
    S. S. Gill and B. D. Hammock, Distribution and properties of a mammalian soluble epoxide hydrase, Biochem. Pharmacol. 29: 389 (1980).PubMedCrossRefGoogle Scholar
  9. 9.
    F. Oesch, D. M. Jerina, J. W. Daly,3A radiometric assay for hepatic epoxide hydrase activity with 7- H-styrene oxide, Biochim. Biophys. Acta 227: 685 (1971).PubMedGoogle Scholar
  10. 10.
    F. Desch, A. J. Sparrow and K. L. Platt, Radioactively labelled epoxides part II. (1) Tritium labelled cyclohexene oxide, trans-stilbene oxide and phenanthrene 9,10-oxide, J. Labelled Compound Radiopharm. 17: 93 (1980).CrossRefGoogle Scholar
  11. 11.
    F. Bieri, P. Bentley, F. Waechter and W. Stäubli, Use of primary cultures of adult rat hepatocytes to investigate mechanism of action of nafenopin, a hepatocarcinogenic peroxisome proliferator, Carcinogenesis 5: 1033 (1984).PubMedCrossRefGoogle Scholar
  12. 12.
    I. Mertes, R. Fleischmann, H. R. Glatt and F. Oesch, Interindividual variations in the activities of cytosolic and microsomal epoxide hydrolase in human liver, Carcinogenesis 6: 219 (1985).PubMedCrossRefGoogle Scholar
  13. 13.
    J. Seidegärd, J. W. DePierre and R. W. Pero, Measurement and characterisation of membrane-bound and soluble epoxide hydrolase activities in resting mononuclear leukocytes from human blood, Cancer Res. 44: 3654 (1984).Google Scholar
  14. 14.
    F. Oesch, A. Zimmer and H. R. Glatt, Microsomal epoxide hydrolase in different rat strains, Biochem. Pharmacol. 32: 1763 (1983).CrossRefGoogle Scholar
  15. 15.
    F. Desch, H. R. Glatt and H. Schmassmann, The apparent ubiquity of epoxide hydratase in rat organs, Biochem. Pharmacol. 26: 603 (1977).CrossRefGoogle Scholar
  16. 16.
    B. D. Hammock and K. Ota, Differential induction of cytosolic epoxide hydrolase, microsomal epoxide hydrolase, and glutathione S-transferase activities, Toxicol. Appl. Pharmacol. 71: 254 (1983).PubMedCrossRefGoogle Scholar
  17. 17.
    F. Waechter, F. Bieri, W. Stäubli and P. Bentley, Induction of cytosolic and microsomal epoxide hydrolases by the hypolipidaemic compound nafenopin in the mouse liver, Biochem. Pharmacol. 33: 31 (1984).PubMedCrossRefGoogle Scholar
  18. 18.
    A. J. Cohen and P. Grasso, Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man, Fd. Cosmet. Toxicol. 19: 585 (1981).CrossRefGoogle Scholar
  19. 19.
    J. K. Reddy, D. L. Azarnoff and C.E. Hignite, Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens, Nature 283: 397 (1980).PubMedCrossRefGoogle Scholar
  20. 20.
    J. K. Reddy and N. D. Lalwani, Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans, CRC Critical Reviews in Toxicology 12 (1): 1 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Franz Oesch
    • 1
  • Ludwig Schladt
    • 1
  • Renate Hartmann
    • 1
  • Christopher Timms
    • 1
  • Walter Wörner
    • 1
  1. 1.Institut für ToxikologieUniversität MainzD-65 MainzGermany

Personalised recommendations